Preeclampsia Treatment Aspirin/Clampsilin: Oxidative Stress, sFlt-1/PIGF Soluble Tyrosine Kinase 1, and Placental Growth Factor Monitoring
- PMID: 39769260
- PMCID: PMC11676860
- DOI: 10.3390/ijms252413497
Preeclampsia Treatment Aspirin/Clampsilin: Oxidative Stress, sFlt-1/PIGF Soluble Tyrosine Kinase 1, and Placental Growth Factor Monitoring
Abstract
The present study aimed to investigate and compare oxidative stress biomarkers and antioxidant enzyme activity in the serum of women at risk of developing preeclampsia (PE) to prevent adverse pregnancy outcomes through early intervention. Changes in soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) levels were measured between 11 and 13 gestational weeks (gw.) before the onset of preeclampsia and its associated complications. This study evaluated the feasibility of the sFlt-1/PlGF biomarker ratio in predicting preeclampsia and adverse pregnancy outcomes, with the goal of preventive therapy with acetylsalicylic acid (150 mg daily), with acetylsalicylic acid (75 mg daily) and Clampsilin. For this purpose, the following were evaluated: (1) the levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) as parameters of oxidative stress; (2) lipid oxidation; (3) antioxidant enzyme activity; and (4) cytokine production. Analysis of the results showed that pregnant women at risk of preeclampsia had significantly higher levels of ROS, lipid oxidation, and superoxide anion radical (•O2-) levels compared to normal pregnancies. In PE, depleted levels of nitric oxide (NO), impaired NO synthase system (NOS), and reduced antioxidant enzyme activity (p < 0.03) suggest that PE patients cannot compensate for oxidative stress (OS). In conclusion, oxidative stress in PE plays a key role, which arises from placental problems and affects both mother and baby. The groups with acetylsalicylic acid therapy (150 mg and 75 mg) were better affected compared to those on Clampsillin.
Keywords: NO; NOS; oxidative stress; preeclampsia; pregnancy.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.Am J Obstet Gynecol. 2016 Dec;215(6):782.e1-782.e9. doi: 10.1016/j.ajog.2016.07.056. Epub 2016 Aug 5. Am J Obstet Gynecol. 2016. PMID: 27503620
-
Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?J Obstet Gynaecol Res. 2019 Sep;45(9):1828-1836. doi: 10.1111/jog.14038. Epub 2019 Jul 1. J Obstet Gynaecol Res. 2019. PMID: 31257726
-
Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia.BMC Pregnancy Childbirth. 2015 Aug 25;15:189. doi: 10.1186/s12884-015-0624-y. BMC Pregnancy Childbirth. 2015. PMID: 26303772 Free PMC article.
-
[Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians].Nephrol Ther. 2019 Nov;15(6):413-429. doi: 10.1016/j.nephro.2018.10.005. Epub 2019 Mar 30. Nephrol Ther. 2019. PMID: 30935786 Review. French.
-
Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.Hypertension. 2020 Apr;75(4):918-926. doi: 10.1161/HYPERTENSIONAHA.119.13763. Epub 2020 Feb 17. Hypertension. 2020. PMID: 32063058 Free PMC article. Review.
References
-
- Ortega M.A., Fraile-Martínez O., García-Montero C., Sáez M.A., Álvarez-Mon M.A., Torres-Carranza D., Álvarez-Mon M., Bujan J., García-Honduvilla N., Bravo C., et al. The pivotal role of the placenta in normal and pathological pregnancies: A focus on preeclampsia, fetal growth restriction, and maternal chronic venous disease. Cells. 2022;11:568. doi: 10.3390/cells11030568. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous